Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model

Nishikawa, 2006, Inhibition of in vivo angiogenesis by N-beta-alanyl-5-S-glutathionyl-3,4 dihydroxyphenylalanine, Eur. J. Pharmacol., 539, 151, 10.1016/j.ejphar.2006.03.084 Masuda, 2006, Antitumor effect of kigamicin D on mouse tumor models, J. Antibiot. (Tokyo), 59, 209, 10.1038/ja.2006.29 Basaki, 2001, Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor, Angiogenesis, 4, 163, 10.1023/A:1014059528046 Tashiro, 1989, Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data, Biomed. Pharmacother., 43, 251, 10.1016/0753-3322(89)90004-8 Yonekura, 1999, UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice, Clin. Cancer Res., 5, 2185 Suzuki, 2008, Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome, Int. J. Pharm., 346, 143, 10.1016/j.ijpharm.2007.06.010 Pendyala, 1993, In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin, Cancer Res., 53, 5970 Yu, 2007, Synthesis and anticancer activity of lipophilic platinum(II) complexes of 3,5-diisopropylsalicylate, Eur. J. Med. Chem. Hofheinz, 2005, Liposomal encapsulated anti-cancer drugs, Anticancer Drugs, 16, 691, 10.1097/01.cad.0000167902.53039.5a Dudek, 2003, Molecular targets in the inhibition of angiogenesis, Expert Opin. Ther. Targets, 7, 527, 10.1517/14728222.7.4.527 Shimizu, 2004, Cancer anti-angiogenic therapy, Biol. Pharm. Bull, 27, 599, 10.1248/bpb.27.599 Ye, 2008, Inhibitory effect of electrolyzed reduced water on tumor angiogenesis, Biol. Pharm. Bull., 31, 19, 10.1248/bpb.31.19 Thurston, 1998, Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice, J. Clin. Invest., 101, 1401, 10.1172/JCI965 Kerbel, 2000, Tumor angiogenesis: past, present and the near future, Carcinogenesis, 21, 505, 10.1093/carcin/21.3.505 Pandya, 2006, Angiogenesis—a new target for future therapy, Vasc. Pharmacol., 44, 265, 10.1016/j.vph.2006.01.005 Asahara, 1999, VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells, Embo J., 18, 3964, 10.1093/emboj/18.14.3964 Lyden, 2001, Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth, Nat. Med., 7, 1194, 10.1038/nm1101-1194 Staton, 2004, Current methods for assaying angiogenesis in vitro and in vivo, Int. J. Exp. Pathol., 85, 233, 10.1111/j.0959-9673.2004.00396.x Hussain, 2008, Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis, Angiogenesis, 11, 245, 10.1007/s10456-008-9108-2 Kumar, 1998, Regulation of distinct steps of angiogenesis by different angiogenic molecules, Int. J. Oncol., 12, 749 Shibusa, 1998, Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma, Clin. Cancer Res., 4, 1483 Rosen, 2002, Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers, Cancer Control, 9, 36, 10.1177/107327480200902S05 Folkman, 1992, The role of angiogenesis in tumor growth, Semin. Cancer Biol., 3, 65 Asano, 1995, Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121, Cancer Res., 55, 5296 Millauer, 1996, Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo, Cancer Res., 56, 1615 Campbell, 2002, Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors, Cancer Res., 62, 6831 Strieth, 2004, Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature, Int. J. Cancer, 110, 117, 10.1002/ijc.20083 Kalra, 2006, Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: implications for tumor vascular targeting, Pharm. Res., 23, 2809, 10.1007/s11095-006-9113-3 Nakamura, 1999, Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis, Eur. J. Pharmacol., 386, 33, 10.1016/S0014-2999(99)00765-7 Oikawa, 1997, Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo, Anticancer Res., 17, 1881 Bartlett, 1959, Colorimetric assay methods for free and phosphorylated glyceric acids, J. Biol. Chem., 234, 469, 10.1016/S0021-9258(18)70227-5 Nomura, 1998, Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors, Pharm. Res., 15, 128, 10.1023/A:1011921324952 Takeuchi, 2003, Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer, Cancer, 97, 2027, 10.1002/cncr.11283 Allen, 2002, Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol), Biosci. Rep., 22, 225, 10.1023/A:1020186505848 Gomer, 1991, Preclinical examination of first and second generation photosensitizers used in photodynamic therapy, Photochem. Photobiol., 54, 1093, 10.1111/j.1751-1097.1991.tb02133.x Henderson, 1992, How does photodynamic therapy work?, Photochem. Photobiol., 55, 145, 10.1111/j.1751-1097.1992.tb04222.x Jain, 1997, Quantitative angiogenesis assays: progress and problems, Nat. Med., 3, 1203, 10.1038/nm1197-1203 de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J. Clin. Oncol., 18, 2938, 10.1200/JCO.2000.18.16.2938 Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study, J. Clin. Oncol., 22, 229, 10.1200/JCO.2004.05.113 Grothey, 2003, Oxaliplatin-safety profile: neurotoxicity, Semin. Oncol., 30, 5, 10.1016/S0093-7754(03)00399-3 Pietrangeli, 2006, Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up, Eur. Neurol., 56, 13, 10.1159/000094376